Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies

Reuters11-06

Entrada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies

Entrada Therapeutics Inc. has outlined its progress and upcoming milestones across its clinical-stage neuromuscular disease programs. The company expects to have four clinical-stage programs by the end of 2025, with key data readouts anticipated in 2026 for ENTR-601-44 and ENTR-601-45. Phase 1/2 multiple ascending dose (MAD) study patient data for ENTR-601-44 is expected in the second quarter of 2026, while similar data for ENTR-601-45 is anticipated in mid-2026. ENTR-601-50 is set to begin a Phase 1/2 MAD study in the UK, with an EU regulatory filing expected in the second half of 2026. Additionally, Vertex Pharmaceuticals is progressing VX-670 for myotonic dystrophy type 1 (DM1) in collaboration with Entrada, with completion of MAD patient enrollment and dosing targeted for the first half of 2026. Entrada also reports a cash balance of approximately $327 million, projecting a cash runway into the third quarter of 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581677900?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581677900","market":"fut","top_or_hot":-1,"title":"Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Entrada Therapeutics Inc. has outlined its progress and upcoming milestones across its clinical-stage neuromuscular disease programs. The company expects to have four clinical-stage programs by the end of 2025, with key data readouts anticipated in 2026 for ENTR-601-44 and ENTR-601-45. Phase 1/2 multiple ascending dose (MAD) study patient data for ENTR-601-44 is expected in the second quarter of 2026, while similar data for ENTR-601-45 is anticipated in mid-2026. ENTR-601-50 is set to begin a Phase 1/2 MAD study in the UK, with an EU regulatory filing expected in the second half of 2026. Additionally, Vertex Pharmaceuticals is progressing VX-670 for myotonic dystrophy type 1 (DM1) in collaboration with Entrada, with completion of MAD patient enrollment and dosing targeted for the first half of 2026. Entrada also reports a cash balance of approximately $327 million, projecting a cash runway into the third quarter of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Entrada Therapeutics Inc. has outlined its progress and upcoming milestones across its clinical-stage neuromuscular disease programs. The company expects to have four clinical-stage programs by the end of 2025, with key data readouts anticipated in 2026 for ENTR-601-44 and ENTR-601-45. Phase 1/2 multiple ascending dose (MAD) study patient data for ENTR-601-44 is expected in the second quarter of 2026, while similar data for ENTR-601-45 is anticipated in mid-2026. ENTR-601-50 is set to begin a Phase 1/2 MAD study in the UK, with an EU regulatory filing expected in the second half of 2026. Additionally, Vertex Pharmaceuticals is progressing VX-670 for myotonic dystrophy type 1 (DM1) in collaboration with Entrada, with completion of MAD patient enrollment and dosing targeted for the first half of 2026. Entrada also reports a cash balance of approximately $327 million, projecting a cash runway into the third quarter of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE0002141913.USD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4rCWbV:1","article_id":"2581677900","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581677900","pubTimestamp":1762431840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Entrada Therapeutics Inc. has outlined its progress and upcoming milestones across its clinical-stage neuromuscular disease programs. The company expects to have four clinical-stage programs by the end of 2025, with key data readouts anticipated in 2026 for ENTR-601-44 and ENTR-601-45. Phase 1/2 multiple ascending dose  study patient data for ENTR-601-44 is expected in the second quarter of 2026, while similar data for ENTR-601-45 is anticipated in mid-2026. ENTR-601-50 is set to begin a Phase 1/2 MAD study in the UK, with an EU regulatory filing expected in the second half of 2026. Additionally, Vertex Pharmaceuticals is progressing VX-670 for myotonic dystrophy type 1  in collaboration with Entrada, with completion of MAD patient enrollment and dosing targeted for the first half of 2026. Entrada also reports a cash balance of approximately $327 million, projecting a cash runway into the third quarter of 2027. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4532":"文艺复兴科技持仓","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","VRTX":"福泰制药","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4585":"ETF&股票定投概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU1674673428.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AC\" (USD) ACC","BK4567":"ESG概念","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4139":"生物科技","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1778281490.HKD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","TRDA":"Entrada Therapeutics, Inc.","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE00BZ9MQY76.HKD":"FTGF CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (HKD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC"},"translate_title":"Entrada Therapeutics公布神经肌肉疾病疗法的管线进展和临床里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRDA":0.9,"VRTX":0.9},"content_text":"Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Neuromuscular Disease Therapies\n    \n\n        Entrada Therapeutics Inc. has outlined its progress and upcoming milestones across its clinical-stage neuromuscular disease programs. The company expects to have four clinical-stage programs by the end of 2025, with key data readouts anticipated in 2026 for ENTR-601-44 and ENTR-601-45. Phase 1/2 multiple ascending dose (MAD) study patient data for ENTR-601-44 is expected in the second quarter of 2026, while similar data for ENTR-601-45 is anticipated in mid-2026. ENTR-601-50 is set to begin a Phase 1/2 MAD study in the UK, with an EU regulatory filing expected in the second half of 2026. Additionally, Vertex Pharmaceuticals is progressing VX-670 for myotonic dystrophy type 1 (DM1) in collaboration with Entrada, with completion of MAD patient enrollment and dosing targeted for the first half of 2026. Entrada also reports a cash balance of approximately $327 million, projecting a cash runway into the third quarter of 2027. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581677900","isCrawlerRequest":true}